To include your compound in the COVID-19 Resource Center, submit it here.

EC approves Samsung Bioepis' trastuzumab biosimilar

Samsung Bioepis Co. Ltd. said the European Commission approved Ontruzant (SB3), a biosimilar of cancer drug

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE